OCUP News and Press, Ocuphire Pharma Inc Com From 03/29/22

Gainers: IGM Biosciences (IGMS) +105%. China SXT Pharmaceuticals (SXTC) +73%. Clever Leaves Holdings (CLVR) +42%. MicroVision (MVIS) +31%. LianBio (LIAN) +26%. TC Biopharm (TCBP) +26%. Robinhood Markets (HOOD) +25%. Kinnate Biopharma (KNTE) +24%. Auddia (AUUD) +23%. Molecular Templates (...

NeoGenomics (NEO) -29% on Q1 guidance cut; CEO to quit Progenity (PROG) -22% on Q4 earnings release. Stryve Foods (SNAX) -21% releases inaugural shareholder report. Kala Pharmaceuticals (KALA) -19% on Q4 earnings release. Lipocine (LPCN) -15% its partne...

Ocuphire Pharma (NASDAQ:OCUP) said a second late stage study of its eye drop Nyxol for reversing pharmacologically-induced dilation of pupil (mydriasis), met its main goal. The phase 3 trial, dubbed MIRA-3, enrolled 368 people (336 adults and 32 adolescents at or over age 12) w...

Meets Primary Endpoint With 58% Of Nyxol treated Subjects Returning to Baseline Pupil Diameter at 90 Minutes Compared to 6% of Placebo Subjects (p<0.0001) MIRA-3 Confirms Prior MIRA-2 Phase 3 Registration Trial Showing Substantial Benefit in Accelerating Reversal of Mydriasis...

Ocuphire Pharma press release (NASDAQ:OCUP): Q4 GAAP EPS of -$0.35 misses by $0.09. As of December 31, 2021 cash and cash equivalents of approximately $24.5 million. Research and development expenses of $4.7 million For further details see: Ocuphire Pharma GAAP EPS of -$0.35 misses by $...

Building Momentum with Completion of Patient Enrollment in 4 Late-Stage Trials Multiple Late-Stage Clinical Trial Data Catalysts in 2022: – Nyxol ® MIRA-3 Phase 3 Results Expected End of 1Q 2022 – MIRA-4 Pediatric, and LYNX-1 Phase 3 Results Expe...

Successful Execution and Completion of Enrollment in Four Late-Stage Clinical Trials Across Nyxol and APX3330 Programs in First Quarter of 2022 APX3330 as an Oral Therapy Has the Potential to Treat Over 7 Million Diabetic Retinopathy Patients With Limited Treatm...

FARMINGTON HILLS, Mich., March 10, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that Mina So...

Ocuphire Pharma (NASDAQ:OCUP) said it completed enrollment in a study, dubbed MIRA-4, evaluating its eye drops Nyxol to reverse pharmacologically-induced mydriasis (RM) in 23 children aged 3-to-11 years old. RM is an unusual dilation or widening of the pupils. The company expects data fr...

With Growing Rate of Childhood Myopia, MIRA-4 Trial Supports a Potential Broader RM Label for Nyxol in Pediatric Subjects 3 to 11 Years Ocuphire Delivering on Execution Early in 2022, Momentum Builds with Completion of Patient Enrollment in 3 Late-Stage Trials for Nyxol Up...